Additional European Equity News - 15th September 2026

Big Yellow Group (BYG LN) - Co. announces that it has contracted to sell its industrial estate in Staines, Surrey for GBP 36.5mln and has received the GBP 2mln retention held back from the previously announced sale of its Harrow industrial estate. (Big Yellow Group) GSK (GSK LN) - Co. announces that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, with plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027. (GSK) Novo Nordisk (NOVOB DC) - Ascendis Pharma (ASND) plans to advance once-monthly TransCon Semaglutide for obesity and type 2 diabetes after regaining exclusive metabolic and cardiovascular rights from Novo Nordisk. The terminated collaboration will return all related licences to Ascendis with no continuing financial obligations between the companies. (Ascendis) Prysmian (PRY IM) - Co. announces that the acquisition of Atkore (ATKR) has received US antitrust clearance. (Prysmian) Tele2 (TEL2B SS) - Co. appoints Vahdat Zehtab as EVP Chief Commercial Officer. (Tele2) Telefonica (TEF SM) - Co. enters into an agreement with DAZN for the distribution of La Liga package for 5 seasons, valued at EUR 330mln on average per season. (Newswires) TotalEnergies (TTE FP) - Co. announces a 3-year joint programme with Mistral, with investment totalling over EUR 100mln, to develop a new generation of frontier AI models to support TotalEnergies' geosciences experts in the exploration, characterisation and development of oil and gas reservoirs. (TotalEnergies) AstraZeneca (AZN LN) upgraded to Hold from Sell at Deutsche Bank